Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Haematologica 2021 Mar 18;[EPub Ahead of Print], KA Rogers, PA Thompson, JN Allan, M Coleman, JP Sharman, BD Cheson, D Jones, R Izumi, MM Frigault, C Quah, RK Raman, P Patel, MH Wang, TJ KippsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.